Trial Profile
Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With Cp 751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Figitumumab (Primary) ; Erlotinib
- Indications Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms ADVIGO
- Sponsors Pfizer
- 14 Oct 2021 This trial has been completed in France (End Date: 26 Apr 2012), according to European Clinical Trials Database record.
- 21 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 29 May 2012 Actual patient number changed from 582 to 583 as reported by ClinicalTrials.gov.